Revance Therapeutics Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$3.81 |
Market Cap |
$561.97 M |
Shares Outstanding |
44.01 M |
Public Float |
37.85 M |
Address |
7555 Gateway Boulevard Newark California 94560 United States |
Employees | - |
Website | http://www.revance.com |
Updated | 07/08/2019 |
Revance Therapeutics, Inc. is a clinical stage biopharmaceutical company. It is engaged in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. |